The Fast Track To Selecting Your Next Cancer Treatment
Our Rapid Therapy Selection™ Test evaluates a broad range of FDA-approved drug options to assess their potential for treating your unique cancer.
Results in 2 days
We’ll deliver a test report to the ordering physician two days after your sample collection. That’s the fastest turnaround time for cancer therapy guidance.
Drugs for your Cancer
Our lab tests a panel of FDA-approved drugs on your live cancer cells. Our drug catalog is growing, including over 100 unique options.
Better Outcomes
In early studies, our innovative test matched the actual responses of 80% of treatments. Our predictive accuracy is being validated in multiple clinical studies.
Get Early Access to Breakthrough Cancer Drug Testing Technology
A cancer diagnosis can undermine your sense of control. The words, “We can try…” rarely restore it.
Our Rapid Therapy Selection™ Test moves cancer treatment beyond trial and error with innovative, proprietary technology developed at MIT. We test live cancer cells outside the body against FDA-approved drugs and measure how they respond precisely.
Travera gives you the information you need to take control of your cancer care. In an unprecedented two-day turnaround time, you will know which drug options have the best potential to work for your unique cancer.
Your Expanded Cancer Treatment Plan
While the FDA has approved many drugs to treat specific cancers, every cancer patient’s cells are unique. Not all approved drugs work for all people at every cancer stage. Your physician, assisted by Travera’s experts, will define the panel of cancer drugs and drug combinations to be tested, based on your cancer type and stage.
You can have a panel of up to 20 FDA-approved drugs tested per test order to determine which drugs or drug combinations have the potential to disrupt the growth of your cancer cells.
Embrace Hope
Travera is home to a leading team of research and clinical experts, with training and experience from the world’s top institutions. We are committed to bringing hope and improved clinical outcomes to cancer patients worldwide.
We are excited by the results from our preliminary clinical studies and multiple clinical research studies at major medical institutions throughout the United States. While our evidence is still small, it is growing.